Skip to main content
Evidence Snapshot

LOX IMVI

CHEMBL614096 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:00:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614096
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats LOX IMVI as ChEMBL target CHEMBL614096. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
LOX IMVI
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614096
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why LOX IMVI matters

As of 2026-09-13

LOX IMVI is reviewed as LOX IMVI; the current evidence base includes 30 approved drugs, 40585 compounds, and 953 assays, with lead potency reaching pChEMBL 9.6.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 30 approved drugs, 40585 compounds, and 953 assays for this target. The dominant activity type is IC50. CHEMBL18155 is the current potency anchor at pChEMBL 9.6.

Use CHEMBL18155 as the tractability anchor when discussing potency (pChEMBL 9.6).

Activity source · ChEMBL 36 via Core Engine
30 approved pChEMBL 9.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why LOX IMVI matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

40585
Total Compounds
953
Total Assays
30
Approved Drugs
IC50: 352.0, EC50: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL18155
 9.6 IC50 —
No preferred name
CHEMBL128315
 9.3 IC50 —
No preferred name
CHEMBL38957
 9.2 IC50 —
No preferred name
CHEMBL44919
 9.1 IC50 —
No preferred name
CHEMBL341028
 9.0 IC50 —

Approved Drugs

Structure Compound First Approval
SELUMETINIB
CHEMBL1614701
 2020
TEMSIROLIMUS
CHEMBL1201182
 2007
DASATINIB
CHEMBL5416410
 2006
GEMCITABINE
CHEMBL888
 1996
TOPOTECAN
CHEMBL84
 1996
DOCETAXEL
CHEMBL3545252
 1995
VINORELBINE
CHEMBL553025
 1994
PACLITAXEL
CHEMBL428647
 1992
MITOMYCIN
CHEMBL105
 1981
DOXORUBICIN
CHEMBL53463
 1974
CYTARABINE
CHEMBL803
 1969
VINBLASTINE
CHEMBL159
 1965
METHOTREXATE
CHEMBL34259
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:00:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614096